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Abstract
The problems associated with the ageing immune system and vaccination were discussed recently
at an international workshop at the Jenner Institute for Vaccine Research, Compton, UK, 6–7
October, 2005. This is a commentary on that session. The meeting included discussions on T and
B cell differentiation and ageing, as well as dendritic cell and neutrophil data, with the emphasis on
T cell immunosenescence, perceived as the most important hindrance to satisfactory responses to
vaccines in the elderly. The main questions to be addressed in this context are the reasons for
dysfunctionality of T cells in the elderly and what to do to improve T cell function. Several of the
major reasons for poor T cell responses in the elderly were discussed; however, many important
questions remain: The next meeting at the Jenner Institute may already be able to provide some of
the answers to these questions, which have serious implications for public health issues in
increasingly elderly populations.
Introduction
An international workshop on Immunosenescence and
Vaccination was organised at the Jenner Institute for Vac-
cine Research, Compton, UK, 6–7 October, 2005 by Peter
Beverley (Jenner Institute), Arne Akbar (University Col-
lege, London, UK) and Don Palmer (Royal Veterinary
College, London, UK). The most profound clinical impact
of age on the immune system concerns the response of the
elderly to vaccination. The meeting included discussions
on T and B cell differentiation and ageing, as well as den-
dritic cell and neutrophil data, with the emphasis on T cell
immunosenescence, perceived as the most important hin-
drance to satisfactory responses to vaccines in the elderly.
The main questions to be addressed in this context are the
reasons for dysfunctionality of T cells in the elderly and
what to do to improve T cell function.
What is the problem?
Several of the major reasons for poor T cell responses in
the elderly were discussed: is it a problem of stem cells
with decreased potential for differentiation into naïve T
cells? Is it a problem of the thymic environment not sup-
porting this differentiation sufficiently any more? Is it a
problem of naïve T cell ageing in the periphery and/or
memory cell ageing and loss? The answers as they are
emerging of course suggest that all these problems, and
more, apply, as outlined below.
Diana Wallace and Peter Beverley [1] at the Jenner Insti-
tute, together with Derek Macallan in London, measured
T cell turnover during human ageing by assessing the rate
of uptake of deuterated glucose into DNA and its dilution
with cell division. In healthy young people, CD45RO+
cells divide more rapidly than CD45RA+ cells in both the
CD4 and CD8 subsets, whereby CD45RO+ cells have a 26
day half-life, with 2.7% of cells dividing every day,
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whereas the RA+ cells have a 154 day half-life and only
0.5% divide every day. Rather surprisingly, perhaps, this is
the same in young and old, so these findings already sug-
gest that memory T cells are turning over faster than naïve
T cells. As the naïve cell division rate is the same in the eld-
erly and the young, it is likely that naïve cells in the elderly
have accumulated a larger number of population dou-
blings during the life of the individual. This is consistent
with and indeed explains the data on naïve cell ageing in
mice from Laura Haynes [2] (Trudeau Institute, Saranac
Lake, NY). However, it also suggests that if memory cell
division is more rapid, replicative senescence of this pop-
ulation should occur faster. However, the rate of attrition
of CD8+ CD45RA+ primed T cells was lower in the elderly
than the young (by a factor > 10), and these persistent
cells contained large clonal populations. This probably
reflects acquisition of apoptosis-resistance by senescent
CD8 cells and their accumulation in a dysfunctional state,
as later described by Graham Pawelec [3] (Center for Med-
ical Research, University of Tübingen, Germany). As these
clonal expansions were to a great degree associated with
seropositivity for Cytomegalovirus in the young, such
data are consistent with many others presented here and
elsewhere suggesting that CMV is a major driving force
behind many of the measured manifestations of immu-
nosenescence in humans. During this talk and others,
there was much discussion on the impact of CMV on the
human immune system and whether CMV in some way
regulated (prevented) cell death in virus-specific, or even
bystander, CD8 populations.
Role of persistent antigenic stimulation
Chronic antigenic stimulation over a lifetime via a source
resistant to elimination (persistent Herpes viruses, para-
sites, cancer, even autoantigens) may result in deleterious
effects on the immune system. There is now a good body
of evidence regarding the impact of CMV, and to a lesser
extent, EBV infection on CD8 cells in young and elderly
humans, but knowledge of its effects on CD4 cells is less
well-developed, and on NK cells in the elderly almost
lacking. However, Paul Moss [4] (Dept Cancer Studies,
University of Birmingham, UK) reported preliminary
studies showing little effect of CMV on NK cells, B cells or
regulatory T cells in the elderly. He emphasised that CMV
negatively influenced the number of naïve CD8 cells in
the elderly and suggested that CMV accelerated age-asso-
ciated processes which occur anyway, probably driven by
other "subdominant" antigens. This is consistent with the
much-discussed idea that chronic antigenic stimulation of
any kind at any age can drive clonal expansions resulting
in overall deleterious effects on immune function.
Advanced age merely results in the accumulation of mul-
tiple such problems. Along these lines, evidence presented
by Janko Nikolich-Zugich [5] (Oregon Health & Science
Unversity, OR, USA) strongly suggests that even sustained
proliferation not dependent on exogenous antigen
(including that induced by lymphopenia or adjuvants)
over a lifetime can induce persistent T cell clonal expan-
sions in specific pathogen-free mice. In addition, he
showed that persistent HSV-1 infection also led to the
accumulation of clones specific for this virus, which also
became dysregulated over time. These events were pre-
vented by continuous antiviral treatment of infected mice,
showing directly that subclinical herpesvirus reactivation
is necessary to drive expansions of memory cells. G.
Pawelec [3] pursued this line of thought by comparing
chronic antigenic stimulation caused by persistent activat-
ing viruses in the elderly with that caused by tumour anti-
gens in (mostly younger) cancer patients, as well as
changes that can be observed in culture models in vitro.
Functionally and phenotypically, many similarities in
CD8 responses can be observed in the elderly and in can-
cer patients. The accumulation of CMV-specific CD8 cells
bearing the hallmarks of anergic cells represents an impor-
tant part of the "Immune Risk Phenotype" (IRP) predic-
tive of mortality in the very elderly [6], and similarly
dysfunctional cells in cancer patients may compromise
the response to the tumour in an analogous fashion. The
emergence of the IRP concept from the longitudinal age-
ing studies carried out by Anders Wikby and others in
Sweden, and studied as a long-term collaborative project
supported by the European Commission (currently under
contract QLK6-CT-2002-02283, coordinated by G.
Pawelec, see http://www.medizin.uni-tuebingen.de/t-cia/
) will hopefully also prove useful for assessing "biomark-
ers of immunosenescence" in younger individuals, and
possibly cancer patients, as well. Recent work from the
group has shown that CD8 clonal expansions driven pre-
dominantly by CMV (but also with EBV playing a part)
begin already in early middle-age. We now know that
remaining life expectancy in the very elderly (>85 yr) cor-
relates with having greater numbers of different clonal
expansions compared to those with few clonal expansions
(but note that all individuals possess very large overall
numbers of CMV-specific CD8 cells) [7]. We explain this
by hypothesising that CMV drives clonal expansions of
multiple CD8 cells recognising different CMV epitopes (in
the young, up to 10% of the T cell repertoire is already
obsessed with CMV, as shown by P. Moss [8] in his pres-
entation). The number of different clones expanded
increases with age, as does the overall number of CD8
cells recognising CMV epitopes. However, in very
advanced age, this clonal diversity starts to shrink, as
apoptosis-resistant senescent cells are more slowly lost by
attrition (via a process not yet clarified) and individuals
possessing only a small number of clonal expansions are
now more at risk of death than those still retaining a larger
repertoire. Why this is so, is also not yet clear, but it is felt
unlikely that they die of CMV disease.Immunity & Ageing 2005, 2:16 http://www.immunityageing.com/content/2/1/16
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The presumably important role of CMV-specific CD4 cells
in this context has not yet been assessed. In this direction,
Arne Akbar [9] presented his studies on the functional sta-
tus of CD4 cells in the elderly using assays which only
reveal non-anergic cells, unlike the studies on CD8 cells,
which revealed larger numbers of dysfunctional cells. This
is because the production of equivalent MHC class II mul-
timers is technically much more challenging than the class
I reagents used for CD8 cells. Nonetheless, the data on
those CMV-specific CD4 cells in the elderly which did
remain functional were extremely informative. In serop-
ositive donors, CMV-specific cells had shorter telomeres,
a sign of increased proliferative history. CMV lysates stim-
ulated secretion of type I interferon (IFN-α) from den-
dritic cells, which acted to inhibit telomerase function in
all virus-specific cells (not just the CMV-specific cells) and
to increase the fraction of CD27- CD28- cells. This may
explain the unexpected finding that CTL in CMV-seropos-
itives possess more differentiated phenotypes, whether
they are CMV-specific or specific for unrelated antigens.
What can be done to rejuvenate the elderly 
immune system?
Targeted neutralisation of CMV-stimulated IFN-α produc-
tion might be beneficial in the CMV-positive elderly,
according to the above-mentioned results. Other possibil-
ities include the use of anti-viral agents or therapeutic vac-
cination, but neither of these approaches is likely to be
available in the near future for use in the elderly. Nonethe-
less, agents such as valacyclovir have been developed,
which have a good safety record in younger people and
might be applicable to the elderly. Similarly, it seems
unlikely that adoptive immunotherapy with ex-vivo-gen-
erated CMV-specific CD8 cells, despite being semi-routine
in stem cell transplant recipients, would ever be easily
transferable to the elderly. The elimination of the dysfunc-
tional CMV-specific CD8 cells might be beneficial in
removing potentially suppressive cells, or at the very least,
simply making "space" for naïve cells that could in theory
still be generated from residual thymic islands present in
most elderly. How to target these, while leaving the func-
tional CMV-specific cells intact, however, is a critical issue.
Perhaps combining the use of KLRG-1 and CD57 to elim-
inate double positive cells might be a possibility, as pro-
posed by G. Pawelec, because it is the small fraction of
KLRG1+ but CD57- cells which seems to retain function-
ality in the elderly. One other possibility might be positive
selection of the CMV-specific cells with a naïve phenotype
(a very small number of which are present in most elderly,
it seems) and expanding these ex vivo using IL 15. How-
ever, this would also require radical treatment involving
ex vivo culture and adoptive immunotherapy, which
might be practically difficult in the elderly. Along these
lines, P. Beverley reported that naïve CD8 cells main-
tained in long-term culture in this way retained their naïve
phenotype. These cultured cells upregulated telomerase
and actually increased telomere length. This approach
clearly also relies on the presence of naïve cells in the eld-
erly, which could be isolated and expanded in culture.
However, according to Beatrix Grubeck-Loebenstein [10]
(Institute for Biology of Ageing, Innsbruck, Austria), there
may not actually be any. She reported her search for truly
naïve cells in the elderly, obtained by isolating CD8+
CD28+ CD45RA+ CD62L+ cells. Theoretically, these
should be naïve, but she found that this subset also had
shorter telomeres in the old than in the young, and, more-
over, clonal spectratyping revealed a smaller repertoire in
the former. So these cells have undergone considerable
division, despite being phenotypially naïve. The implica-
tion is that even naïve cells in the elderly have "aged" in
the same way as has been investigated in detail by L. Hay-
nes [11] in the mouse model. She described that (in this
case CD4+) naïve cells in old mice (CD28+, CD134+,
CXCR5+) had low levels of CD40L expression (although
this could be enhanced by IL 2 – use of which might also
represent a potential avenue to remediation). When all
the CD4 cells were depleted by antibody treatment, and
the animals then left for 2 months to repopulate, new
naïve cells did develop and even in old animals were now
perfectly functional. These results do suggest that deleting
accumulated dysfunctional cells, and allowing repopula-
tion, can indeed "rejuvenate" the T cell system. Nonethe-
less, once again, it does not seem very likely that such
radical approaches would be permitted in elderly people.
However, focussing on the thymus and attempting to
increase output of naïve cells in the elderly, whether or
not combined with peripheral depletion, may still be a
viable method for ameliorating immunosenescence. To
this end, Richard Aspinall (Imperial College, London,
UK) developed the strategy of targeting IL 7 [12] to the
thymus only, to avoid cytokine side effects, by producing
a fusion protein with CCR9, the receptors for which are
expressed exclusively by thymic stromal cells. On chal-
lenge with influenza, mice had a decreased lung viral load
when given the fusion protein, and fewer TNF-α-produc-
ing CD8 cells. The success of this approach requires not
only that naïve cells are still present, but that in addition
to the thymus, T cell progenitors are also still present and
functional in the elderly. However, according to Ken Dor-
shkind [13] (UCLA, Los Angeles, USA), this may not be
the case. He showed that "early T cell progenitors" (ETP;
CD44+ CD25- c-kithigh CD127-) from old animals are
fewer in number, more prone to apoptosis and have less
proliferative capacity than in the young. Thus, if there is a
block in the potential of hematopoietic stem cells to gen-
erate ETP, it would be difficult to see how IL 7 supplemen-
tation would succeed. One final possibility is the well-
established approach of caloric restriction, discussed by J.
Nikolich-Zugich [14] in the rhesus monkey. Calorically-
restricted CMV+ monkeys have maintained numbers ofPublish with BioMed Central    and   every 
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naïve CD8 cells better than ad lib fed animals; they also
had greater numbers of T cell receptor-excision circle-bear-
ing cells (ie those with a lesser proliferative history) and
lower levels of pro-inflammatory factors (TNF-α, IFN-γ).
They also had fewer effector-memory cells. So perhaps
even regarding the deleterious effects of CMV, the advice
to eat less might still be some of the best available.
Conclusion
Many questions remain. If CMV is really having such a dis-
astrous effect in "accelerating" immunosenescence in the
elderly, is it doing the same in the young? Are CMV-seron-
egative elderly donors healthier and do they live longer
(and are centenarians CMV-seronegative?)? If CD4 and
CD8 cells are equally affected, but B cells, dendritic cells
and NK cells are really not (to be confirmed), are all types
of the former equally affected (specifically, what about T-
regulatory cells?)? Does CMV reactivate more frequently
in the at-risk elderly, or does simply the duration of infec-
tion determine the level of immunosenescence? Do at-risk
elderly ever die of disease which is related to CMV reacti-
vation? Do CMV+ elderly people who have entered the
IRP group ever leave it, and is this associated with survival
benefit? Does it matter whether the source of chronic anti-
genic stress is CMV or can other antigens do the same? The
next meeting at the Jenner Institute may already be able to
provide some of the answers to these important questions
which have serious implications for public health issues
in increasingly elderly populations.
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